Denali Advisors LLC acquired a new position in shares of USANA Health Sciences, Inc. (NYSE:USNA - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 16,409 shares of the company's stock, valued at approximately $443,000. Denali Advisors LLC owned about 0.09% of USANA Health Sciences at the end of the most recent quarter.
Several other institutional investors have also modified their holdings of the stock. Exchange Traded Concepts LLC raised its position in USANA Health Sciences by 7.1% during the 1st quarter. Exchange Traded Concepts LLC now owns 9,184 shares of the company's stock worth $248,000 after buying an additional 606 shares during the last quarter. Versant Capital Management Inc grew its stake in shares of USANA Health Sciences by 542.5% during the 1st quarter. Versant Capital Management Inc now owns 1,150 shares of the company's stock worth $31,000 after purchasing an additional 971 shares during the period. Price T Rowe Associates Inc. MD grew its stake in USANA Health Sciences by 15.8% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 7,234 shares of the company's stock valued at $260,000 after acquiring an additional 985 shares during the last quarter. Franklin Resources Inc. grew its stake in USANA Health Sciences by 4.8% in the 4th quarter. Franklin Resources Inc. now owns 22,070 shares of the company's stock valued at $792,000 after acquiring an additional 1,020 shares during the last quarter. Finally, Parallel Advisors LLC grew its stake in USANA Health Sciences by 8,141.2% in the 1st quarter. Parallel Advisors LLC now owns 1,401 shares of the company's stock valued at $38,000 after acquiring an additional 1,384 shares during the last quarter. Hedge funds and other institutional investors own 54.25% of the company's stock.
Insider Transactions at USANA Health Sciences
In other news, CFO G Doug Iiekking sold 4,548 shares of the company's stock in a transaction that occurred on Friday, May 9th. The stock was sold at an average price of $29.61, for a total transaction of $134,666.28. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Walter Noot sold 6,291 shares of the business's stock in a transaction that occurred on Tuesday, May 27th. The shares were sold at an average price of $30.29, for a total value of $190,554.39. The disclosure for this sale can be found here. Insiders sold a total of 12,013 shares of company stock worth $360,149 in the last three months. 0.63% of the stock is currently owned by company insiders.
USANA Health Sciences Price Performance
NYSE USNA traded up $3.68 during mid-day trading on Wednesday, hitting $35.21. The company's stock had a trading volume of 156,160 shares, compared to its average volume of 142,331. USANA Health Sciences, Inc. has a 52-week low of $23.10 and a 52-week high of $46.44. The stock's fifty day simple moving average is $30.69 and its two-hundred day simple moving average is $30.09. The firm has a market capitalization of $655.72 million, a P/E ratio of 19.66, a price-to-earnings-growth ratio of 0.97 and a beta of 0.64.
USANA Health Sciences (NYSE:USNA - Get Free Report) last posted its quarterly earnings results on Tuesday, July 22nd. The company reported $0.74 EPS for the quarter, beating the consensus estimate of $0.54 by $0.20. The business had revenue of $235.85 million during the quarter, compared to analyst estimates of $225.20 million. USANA Health Sciences had a net margin of 3.98% and a return on equity of 8.94%. On average, equities analysts forecast that USANA Health Sciences, Inc. will post 2.45 earnings per share for the current fiscal year.
Analysts Set New Price Targets
Separately, Wall Street Zen upgraded shares of USANA Health Sciences from a "hold" rating to a "buy" rating in a report on Thursday, May 22nd.
Get Our Latest Stock Analysis on USANA Health Sciences
USANA Health Sciences Profile
(
Free Report)
USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.
Recommended Stories

Before you consider USANA Health Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and USANA Health Sciences wasn't on the list.
While USANA Health Sciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.